|
1
|
Shi JF, Cao M, Wang Y, Bai FZ, Lei L, Peng
J, Feletto E, Canfell K, Qu C and Chen W: Is it possible to halve
the incidence of liver cancer in China by 2050? Int J Cancer.
148:1051–1065. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Xia Y, Li J, Liu G, Wang K, Qian G, Lu Z,
Yang T, Yan Z, Lei Z, Si A, et al: Long-term effects of repeat
hepatectomy vs percutaneous radiofrequency ablation among patients
with recurrent hepatocellular carcinoma: A randomized clinical
trial. JAMA Oncol. 6:255–263. 2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Ding J and Wen Z: Survival improvement and
prognosis for hepatocellular carcinoma: Analysis of the SEER
database. BMC Cancer. 21(1157)2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhang C, Shen Q, Gao M, Li J and Pang B:
The role of cyclin dependent kinase inhibitor 3 (CDKN3) in
promoting human tumors: Literature review and pan-cancer analysis.
Heliyon. 10(e26061)2024.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Barrón EV, Roman-Bassaure E,
Sánchez-Sandoval AL, Espinosa AM, Guardado-Estrada M, Medina I,
Juárez E, Alfaro A, Bermúdez M, Zamora R, et al: CDKN3 mRNA as a
biomarker for survival and therapeutic target in cervical cancer.
PLoS One. 10(e0137397)2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Li WH, Zhang L and Wu YH: CDKN3 regulates
cisplatin resistance to colorectal cancer through TIPE1. Eur Rev
Med Pharmacol Sci. 24:3614–3623. 2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Dai W, Miao H, Fang S, Fang T, Chen N and
Li M: CDKN3 expression is negatively associated with pathological
tumor stage and CDKN3 inhibition promotes cell survival in
hepatocellular carcinoma. Mol Med Rep. 14:1509–1514.
2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Huang R, Guo L, Chen C, Xiang Y, Li G,
Zheng J, Wu Y, Yuan X, Zhou J, Gao W and Xiang S: System analysis
identifies UBE2C as a novel oncogene target for adrenocortical
carcinoma. PLoS One. 18(e0289418)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shi T, Hu Z, Tian L and Yang Y: Pan-cancer
landscape of CENPO and its underlying mechanism in LUAD. Respir
Res. 24(113)2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Szklarczyk D, Kirsch R, Koutrouli M,
Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT,
Pyysalo S, et al: The STRING database in 2023: Protein-protein
association networks and functional enrichment analyses for any
sequenced genome of interest. Nucleic Acids Res. 51:D638–D646.
2023.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gao J, Yang S, Xie G, Pan J and Zhu F:
Integrating network pharmacology and experimental verification to
explore the pharmacological mechanisms of Aloin against gastric
cancer. Drug Des Devel The. 16:1947–1961. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Hu J, Qiu D, Yu A, Hu J, Deng H, Li H, Yi
Z, Chen J and Zu X: YTHDF1 Is a potential pan-cancer biomarker for
prognosis and immunotherapy. Front Oncol. 11(607224)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Hou W, Kong L, Hou Z and Ji H: CD44 is a
prognostic biomarker and correlated with immune infiltrates in
gastric cancer. BMC Med Genomics. 15(225)2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Xie D, Shi J, Zhou J, Fan J and Gao Q:
Clinical practice guidelines and real-life practice in
hepatocellular carcinoma: A Chinese perspective. Clin Mol Hepatol.
29:206–216. 2023.PubMed/NCBI View Article : Google Scholar
|
|
15
|
An L, Zeng HM, Zheng RS, Zhang SW, Sun KX,
Zou XN, Chen R, Wang SM, Gu XY, Wei WW and He J: Liver cancer
epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 41:721–727.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Mori J, Sawada T, Baba T, Hayakawa A,
Kanemoto Y, Nishimura K, Amano R, Siril YJ, Okada M, Kurokawa T and
Kato S: Identification of cell cycle-associated and -unassociated
regulators for expression of a hepatocellular carcinoma oncogene
cyclin-dependent kinase inhibitor 3. Biochem Biophys Res Commun.
625:46–52. 2022.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Deng X, Ma J, Zhou W, Yuan Y, Wang B and
Meng X: GID2 interacts with CDKN3 and regulates pancreatic cancer
growth and apoptosis. Lab Invest. 103(100122)2023.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gao C, Fan X, Liu Y, Han Y, Liu S, Li H,
Zhang Q, Wang Y and Xue F: Comprehensive analysis reveals the
potential roles of CDKN3 in pancancer and verification in
endometrial cancer. Int J Gen Med. 16:5817–5839. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ghafouri-Fard S, Khoshbakht T, Hussen BM,
Dong P, Gassler N, Taheri M, Baniahmad A and Dilmaghani NA: A
review on the role of cyclin dependent kinases in cancers. Cancer
Cell Int. 22(325)2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yu C, Cao H, He X, Sun P, Feng Y, Chen L
and Gong H: Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a
critical role in prostate cancer via regulating cell cycle and DNA
replication signaling. Biomed Pharmacother. 96:1109–1118.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang J, Zhang Y and Zhang J:
N6-Methyladenosine modified circ-NAB1 modulates cell cycle and
epithelial-mesenchymal transition via CDKN3 in endometrial cancer.
Cell Mol Biol (Noisy-le-grand). 70:161–169. 2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Al Sharie AH, Abu Zahra AM, El-Elimat T,
Darweesh RF, Al-Khaldi AK, Abu Mousa BM, Amer MSB, Al Zu'bi YO,
Al-Kammash K, Abu Lil A, et al: Cyclin dependent kinase inhibitor 3
(CDKN3) upregulation is associated with unfavorable prognosis in
clear cell renal cell carcinoma and shapes tumor immune
microenvironment: A bioinformatics analysis. Medicine (Baltimore).
102(e35004)2023.PubMed/NCBI View Article : Google Scholar
|
